comparemela.com

Latest Breaking News On - Improving global outcomes - Page 6 : comparemela.com

Sibeprenlimab Receives U S FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

Sibeprenlimab Receives U S FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin

PRINCETON, N.J. & TOKYO & WALTHAM, Mass. (BUSINESS WIRE) Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designat.

Automated AKI Alert Prompts Change of Care, Shows No Impact on Patient Outcomes

Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.

Patients with IgA Nephropathy May Not Be Receiving Optimal Supportive Care

Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.

Roger A Levy, MD, PhD: The Paradigm Shift in Lupus Nephritis Management

Roger A Levy, MD, PhD, discusses the transformative impact of the KDIGO guidelines, which recommend early initiation of belimumab for lupus nephritis.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.